COMMUNIQUÉS West-GlobeNewswire

Regeneron Announces Investor Conference Presentations
03/11/2025
TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30 p.m. GMT (10:30 a.m. ET [...]
Pyxis Oncology to Participate in Upcoming Investor Conferences
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management will [...]
BBOT to Participate in the Jefferies Global Healthcare Conference in London
03/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
03/11/2025
Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other [...]
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
03/11/2025
The virtual webcast will take place Wednesday, November 12, 2025, at 8 a.m. ET Initial safety data for 32 patients with autoimmune disease treated with AlloNK + monoclonal antibody (mAb) therapy, highlighting a [...]
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
03/11/2025
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday [...]
Option Care Health to Participate in Upcoming Investor Conferences
03/11/2025
BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
03/11/2025
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies FRIENDSWOOD, Texas, Nov. 03, 2025 ( [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly [...]
Bitterroot Bio to Present Anti-CD47 Research at American Heart Association Annual Scientific Session 2025
03/11/2025
PALO ALTO, Calif. and NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, announced today that the Company will present data [...]
Glucotrack, Inc. Encourages Shareholders to Vote
03/11/2025
The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. ( [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/11/2025
LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on [...]
TELA Bio Appoints William Plovanic to Board of Directors
03/11/2025
MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
03/11/2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions
03/11/2025
- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with the FDA to discuss [...]
Zelluna ASA – Key information relating to subsequent offering
04/11/2025
Reference is made to the stock exchange announcement made by Zelluna ASA (the " Company ") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the " Private [...]
Zelluna ASA - Mandatory notification of trade
04/11/2025
Reference is made to the private placement (the " Private Placement ") and the retail offering through PrimaryBid (the " PrimaryBid Offering ") announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR- [...]
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
03/11/2025
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment [...]
Zelluna ASA - Successful private placement and retail offering
03/11/2025
Successful private placement and retail offering - Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK therapy, ZI-MA4-1, into Phase I clinical trials and develop the pipeline Strong [...]

Pages